NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

Abstract The NRG Oncology/NSABP B-47 menstrual history (MH) study examined trastuzumab effects on menstrual status and associated circulating reproductive hormones. MH was evaluated by questions related to hysterectomy, oophorectomy, and reported menstrual changes. Pre/perimenopausal women were asse...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher, Charles E. Geyer, Priya Rastogi, John P. Crown, Michael P. Thirlwell, David M. Ellison, Jean-Francois Boileau, Patrick J. Flynn, Jong-Hyeon Jeong, Eleftherios P. Mamounas, Norman Wolmark
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2fe38dd1eb3c43a496b8bd443b9c9acc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2fe38dd1eb3c43a496b8bd443b9c9acc
record_format	dspace
spelling	oai:doaj.org-article:2fe38dd1eb3c43a496b8bd443b9c9acc2021-12-02T15:53:06ZNRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab10.1038/s41523-021-00264-22374-4677https://doaj.org/article/2fe38dd1eb3c43a496b8bd443b9c9acc2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00264-2https://doaj.org/toc/2374-4677Abstract The NRG Oncology/NSABP B-47 menstrual history (MH) study examined trastuzumab effects on menstrual status and associated circulating reproductive hormones. MH was evaluated by questions related to hysterectomy, oophorectomy, and reported menstrual changes. Pre/perimenopausal women were assessed at entry, 3, 6, 12, 18, 24, 30, and 36 months. Consenting women had estradiol and FSH measurement at entry, 3, 6, 12, 18, and 24 months. Logistic regression determined predictors of amenorrhea and hormone levels at 12, 24, and 36 months. Between 2/8/2011 and 2/10/2015, 3270 women with node-positive/high-risk node-negative HER2-low breast cancer were enrolled. There were 1,458 women enrolled in the MH study; 1231 consented to baseline blood samples. Trastuzumab did not contribute to a higher amenorrhea rate. Amenorrhea predictors were consistent with earlier studies; however, to our knowledge, this is the largest prospective study to include serial reproductive hormone measurements to 24 months and clinical amenorrhea reports to 36 months. These data can help to counsel patients regarding premature menopause risk.Patricia A. GanzReena S. CecchiniLouis FehrenbacherCharles E. GeyerPriya RastogiJohn P. CrownMichael P. ThirlwellDavid M. EllisonJean-Francois BoileauPatrick J. FlynnJong-Hyeon JeongEleftherios P. MamounasNorman WolmarkNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Patricia A. Ganz Reena S. Cecchini Louis Fehrenbacher Charles E. Geyer Priya Rastogi John P. Crown Michael P. Thirlwell David M. Ellison Jean-Francois Boileau Patrick J. Flynn Jong-Hyeon Jeong Eleftherios P. Mamounas Norman Wolmark NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
description	Abstract The NRG Oncology/NSABP B-47 menstrual history (MH) study examined trastuzumab effects on menstrual status and associated circulating reproductive hormones. MH was evaluated by questions related to hysterectomy, oophorectomy, and reported menstrual changes. Pre/perimenopausal women were assessed at entry, 3, 6, 12, 18, 24, 30, and 36 months. Consenting women had estradiol and FSH measurement at entry, 3, 6, 12, 18, and 24 months. Logistic regression determined predictors of amenorrhea and hormone levels at 12, 24, and 36 months. Between 2/8/2011 and 2/10/2015, 3270 women with node-positive/high-risk node-negative HER2-low breast cancer were enrolled. There were 1,458 women enrolled in the MH study; 1231 consented to baseline blood samples. Trastuzumab did not contribute to a higher amenorrhea rate. Amenorrhea predictors were consistent with earlier studies; however, to our knowledge, this is the largest prospective study to include serial reproductive hormone measurements to 24 months and clinical amenorrhea reports to 36 months. These data can help to counsel patients regarding premature menopause risk.
format	article
author	Patricia A. Ganz Reena S. Cecchini Louis Fehrenbacher Charles E. Geyer Priya Rastogi John P. Crown Michael P. Thirlwell David M. Ellison Jean-Francois Boileau Patrick J. Flynn Jong-Hyeon Jeong Eleftherios P. Mamounas Norman Wolmark
author_facet	Patricia A. Ganz Reena S. Cecchini Louis Fehrenbacher Charles E. Geyer Priya Rastogi John P. Crown Michael P. Thirlwell David M. Ellison Jean-Francois Boileau Patrick J. Flynn Jong-Hyeon Jeong Eleftherios P. Mamounas Norman Wolmark
author_sort	Patricia A. Ganz
title	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
title_short	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
title_full	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
title_fullStr	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
title_full_unstemmed	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
title_sort	nrg oncology/nsabp b-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2fe38dd1eb3c43a496b8bd443b9c9acc
work_keys_str_mv	AT patriciaaganz nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT reenascecchini nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT louisfehrenbacher nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT charlesegeyer nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT priyarastogi nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT johnpcrown nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT michaelpthirlwell nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT davidmellison nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT jeanfrancoisboileau nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT patrickjflynn nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT jonghyeonjeong nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT eleftheriospmamounas nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab AT normanwolmark nrgoncologynsabpb47menstrualhistorystudyimpactofadjuvantchemotherapywithandwithouttrastuzumab
_version_	1718385501369532416

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

Ejemplares similares